Indogulf Cropsciences files Annual Report for FY2025-26; 34th AGM on Sep 24, 2026

Pat Growth 25pctEbitda Margin CompressionResults View source PDF Explain this filing

IGCL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.9%Reaction day

₹71.71

prior close

₹72.24

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%+2.5% vs market

Pesticides & Agrochemicals peers, median of 28sector+0.1%+1.7% vs sector

On the reaction day the stock moved 2.5 pts more than Nifty Microcap 250 and 1.7 pts more than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.5

10m

-1.4

15m

-1.4

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.9-0.6+2.5+0.1+1.7

Next day

+1.2+0.0+1.2-0.3+1.5

+1.1+0.7+0.4-0.3+1.4

+1.5+1.1+0.4-1.0+2.5

+0.7+1.6-1.0-0.7+1.4

+1.8+1.5+0.3-1.3+3.1

-5.3+1.4-6.7-3.1-2.2

15d

-12.5+0.4-12.9-3.7-8.8

-25.6-1.4-24.2-7.6-18.0

—————

UpDownMarket · Nifty Microcap 250Sector · Pesticides & Agrochemicals peers, median of 28Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Indogulf Cropsciences filed its 34th Annual Report for FY2025-26. Revenue grew 19% to 7,046 million. EBITDA rose 15% to 740 million (margin 10.4%). PAT jumped 27% to 400 million, EPS at 6.72. Debt-to-equity improved to 0.40 times. Company operates 4 plants, exports to 34+ countries, and listed on BSE and NSE in July 2025 after a 2,000 million IPO. AGM set for September 24, 2026 via video conferencing.

Likely market impact

First full year as a listed firm shows profitable growth with stronger balance sheet. PAT growth outpaced revenue, though EBITDA margin slightly compressed.